glp-1 receptor agonists effectiveness comparison Drug in Diabetes and Obesity Treatment GLP-1 Receptor Agonist Market Growth
Description
[DOI] [PubMed] [Google Scholar] 199.Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z
The company saw an impressive 56% year-over-year (YOY) boost to revenue, thanks in large part to $12.8 billion in combined sales of its two main GLP-1 agonists, Mounjaro and Zepbound
Mustelin, T
[DOI] [PubMed] [Google Scholar] 853.Foltynie T., Aviles-Olmos I
More recent agents include dual agonists such as tirzepatide, which activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors and produces even greater weight loss
However, it comes at a cost
